RT Journal Article
T1 The Role of Immunomodulatory Therapy with Oxiris in COVID-19 with Renal Failure and Immune Dysfunction
A1 Quiles Trasobares, Nerea
A1 Gonzalez Fernandez, Maria
A1 Barea Mendoza, Jesus Abelardo
A1 Arias Verdú, Dolores
A1 Barrueco Francioni, Jesus Emilio
A1 Seller Pérez, Gemma Luisa
A1 Molina Collado, Zaira
A1 Lesmes Gonzalez-de-Aledo, Amanda
A1 Herrera-Gutiérrez, Manuel Enrique
A1 Sánchez Izquierdo Riera, José Ángel
K1 COVID-19
K1 Sistema inmunológico
AB Introduction: The main objective of this study was to evaluate the impact of hemoadsorption on the elimination of inflammatory mediators.Methods: A prospective, bicenter, observational cohort study was conducted between March 2020 and February 2022 to explore the immunomodulatory response, demographic and clinical characteristics of individuals with COVID-19 admitted to the ICU with severe acute respiratory failure and in need of CRRT with Oxiris® with or without AKI.Results: Sixty-four patients were analyzed. Statistically significant differences were observed between exposed and unexposed groups, in relation to the reduction in D-dimer levels -15,614 (24,848.9) versus -4,136.5 (9,913.47) (p 0.031, d: 1.59, 95% CI: -21,830, -1,126). An increase in PCT was observed 0.47 (2.08) versus -0.75 (2.3) (p 0.044 95% CI: 0.03, 2.44). No differences were found in a decrease in CRP -4.21 (7.29) versus -1.6 (9.02) (p 0.22) nor in the rest of inflammatory parameters fibrinogen, IL-6, ferritin, lymphocytes, and neutrophils. Subgroup analysis in patients exposed to therapy also showed a significant decrease in D-dimer of 55% from baseline: 6,000 (1,984.5-27,750) pre-therapy versus 2,700 (2,119.5-6,145) (95% CI: -23,000, -2,489) post-therapy with a strong effect size (p 0.001, d: 0.65).Conclusion: The hemoadsorptive therapy in COVID-19 was associated with a significant decrease in D-dimer parameters without showing decreases in the rest of the clinical, inflammatory parameters and severity scales analyzed.
PB Karger
YR 2024
FD 2024-10
LK https://hdl.handle.net/10630/41259
UL https://hdl.handle.net/10630/41259
LA eng
NO Quílez Trasobares N, González-Fernández M, Barea-Mendoza JA, Arias-Verdú MD, Barrueco-Francioni JE, Seller-Pérez G, Molina-Collado Z, Lesmes González-de Aledo A, Herrera-Gutiérrez M, Sánchez-Izquierdo Riera JÁ. The Role of Immunomodulatory Therapy with Oxiris in COVID-19 with Renal Failure and Immune Dysfunction. Blood Purif. 2024;53(10):804-812. doi: 10.1159/000539833. Epub 2024 Jul 22. PMID: 38991521.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026